Analyst Reco. TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
89.25 ^USD	+0.42%		+2.30%	+13.07%

Apr. 18	Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing	MT
Apr. 05	Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing	Apr. 18	MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing	Apr. 05	MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing	Apr. 02	MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target	Mar. 28	MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating	Feb. 27	MT
Morgan Stanley Adjusts TransMedics Group Price Target to $75 From $54, Maintains Equal Weight Rating	Dec. 04	MT
Morgan Stanley Adjusts Price Target on TransMedics to $54 From $50, Maintains Equal-Weight Rating	Nov. 07	MT
Waning Optimism on Rate Cuts Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Nov. 07	MT
Earnings, Rates Blunt Wall Street Pre-Bell; Asia Down Europe Flat	Nov. 07	MT
Morgan Stanley Adjusts Price Target on TransMedics Group to $50 From $81, Keeps Equalweight Rating	23-10-13	MT
Morgan Stanley Adjusts Price Target on TransMedics to $50 From $81, Maintains Equal-Weight Rating	23-10-13	MT
Oppenheimer Adjusts TransMedics Group Price Target to $92 From $90, Maintains Outperform Rating	23-08-04	MT
William Blair Initiates TransMedics at Outperform	23-07-19	MT
Canaccord Genuity Adjusts Price Target on TransMedics to $86 From $91, Maintains Buy Rating	23-05-18	MT
Morgan Stanley Adjusts Price Target on TransMedics Group to $81 From $74, Maintains Equalweight Rating	23-05-03	MT
Oppenheimer Adjusts TransMedics Price Target to $90 From $85, Maintains Outperform Rating	23-05-02	MT
JPMorgan Stanley Adjusts TransMedics Group's Price Target to $81 From $67, Keeps Overweight Rating	23-02-23	MT
Morgan Stanley Adjusts TransMedics Group's Price Target to $74 From $63, Keeps Equalweight Rating	23-02-23	MT
Cowen Adjusts TransMedics Group's Price Target to $75 From $70, Keeps Outperform Rating	23-02-23	MT
Canaccord Genuity Adjusts Price Target on TransMedics to $78 From $68, Maintains Buy Rating	23-02-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Analyst Reco.

Filters